

Andrew E Hendifar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3391502/publications.pdf>

Version: 2024-02-01

99
papers

6,615
citations

136950

32
h-index

69250

77
g-index

100
all docs

100
docs citations

100
times ranked

9790
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. <i>Pancreatology</i> , 2022, 22, 92-97. | 1.1 | 4 |
| 2 | Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 511-524. | 2.0 | 1 |
| 3 | Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?. <i>Current Oncology Reports</i> , 2022, 24, 819-824. | 4.0 | 4 |
| 4 | Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 100. | 1.0 | 4 |
| 5 | Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 23. | 2.5 | 1 |
| 6 | Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659. | 7.3 | 18 |
| 7 | ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015. | 3.0 | 8 |
| 8 | Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2022, 51, 213-218. | 1.1 | 2 |
| 9 | Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1712-1718. | 5.0 | 12 |
| 10 | Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. <i>Cancers</i> , 2021, 13, 1706. | 3.7 | 19 |
| 11 | Immunotherapy Updates in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2164. | 3.7 | 14 |
| 12 | Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7545-7554. | 1.5 | 2 |
| 13 | Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. <i>Frontiers in Oncology</i> , 2021, 11, 678070. | 2.8 | 6 |
| 14 | A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74. | 5.4 | 27 |
| 15 | Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021, 5, 1325-1338. | 3.0 | 14 |
| 16 | Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. <i>Cancer Medicine</i> , 2021, 10, 7152-7161. | 2.8 | 6 |
| 17 | Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4547. | 3.7 | 12 |
| 18 | Symptom Management in Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 8. | 3.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. <i>Science Advances</i> , 2021, 7, eabi7511. | 10.3 | 23 |
| 20 | Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1959-1968. | 7.3 | 17 |
| 21 | Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510. | 3.7 | 28 |
| 22 | ¹⁷⁷ Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1752-1763. | 10.7 | 195 |
| 23 | A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138432. | 5.9 | 8 |
| 24 | Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. <i>JCO Oncology Practice</i> , 2020, 16, 701-702. | 2.9 | 2 |
| 25 | Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194. | 1.6 | 233 |
| 26 | Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5232. | 4.1 | 7 |
| 27 | Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096431. | 3.2 | 1 |
| 28 | Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. <i>Cancers</i> , 2020, 12, 1168. | 3.7 | 13 |
| 29 | Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 4525-4532. | 1.5 | 13 |
| 30 | Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519. | 3.0 | 1 |
| 31 | Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. <i>JCO Precision Oncology</i> , 2020, 4, 614-619. | 3.0 | 11 |
| 32 | Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2020, 49, 393-407. | 1.1 | 15 |
| 33 | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷ Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382. | 6.4 | 79 |
| 34 | Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. <i>Lancet Oncology</i> , The, 2020, 21, 508-518. | 10.7 | 323 |
| 35 | Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 928-948. | 3.0 | 16 |
| 36 | An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. <i>Endoscopic Ultrasound</i> , 2020, 9, 24. | 1.5 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 377-389. | 1.5 | 3 |
| 38 | Remote Oncology Care: Review of Current Technology and Future Directions. <i>Cureus</i> , 2020, 12, e10156. | 0.5 | 15 |
| 39 | A radiopaque polymer hydrogel as an irreversible electroporation compatible fiducial marker for pancreas stereotactic body radiotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2020, 7, 165-167. | 0.2 | 0 |
| 40 | 318â€¦Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007. , 2020, , . | | 0 |
| 41 | Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. <i>Journal of Surgical Oncology</i> , 2019, 120, 926-931. | 1.7 | 10 |
| 42 | Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. <i>Advances in Radiation Oncology</i> , 2019, 4, 513-519. | 1.2 | 12 |
| 43 | Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. <i>British Journal of Cancer</i> , 2019, 121, 264-270. | 6.4 | 15 |
| 44 | The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. <i>Clinical and Translational Medicine</i> , 2019, 8, 9. | 4.0 | 80 |
| 45 | A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. <i>JAMIA Open</i> , 2019, 2, 505-515. | 2.0 | 56 |
| 46 | Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309. | 2.3 | 6 |
| 47 | 18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation. <i>Advances in Radiation Oncology</i> , 2019, 4, 613-622. | 1.2 | 7 |
| 48 | Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 63-63. | 3.0 | 12 |
| 49 | Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-15. | 3.0 | 14 |
| 50 | Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. <i>PLoS ONE</i> , 2019, 14, e0218580. | 2.5 | 19 |
| 51 | Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2019, 90, 37-44. | 2.0 | 7 |
| 52 | Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 9, 28-34. | 2.9 | 1 |
| 53 | Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. <i>Advances in Radiation Oncology</i> , 2019, 4, 302-313. | 1.2 | 10 |
| 54 | Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4. | 1.3 | 224 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Pancreatic cancer "mismatch"™ in Lynch syndrome. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000274. | 2.7 | 6 |
| 56 | Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. <i>Oncologist</i> , 2019, 24, e1460-e1466. | 3.7 | 42 |
| 57 | Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. <i>JCO Precision Oncology</i> , 2019, 3, 1-10. | 3.0 | 38 |
| 58 | Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. <i>Pancreas</i> , 2019, 48, 1111-1118. | 1.1 | 11 |
| 59 | The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. <i>Oncologist</i> , 2019, 24, 54-61. | 3.7 | 6 |
| 60 | A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. <i>EBioMedicine</i> , 2019, 40, 375-381. | 6.1 | 85 |
| 61 | Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. <i>Oncotarget</i> , 2019, 10, 6260-6268. | 1.8 | 6 |
| 62 | Wearable activity monitors in oncology trials: Current use of an emerging technology. <i>Contemporary Clinical Trials</i> , 2018, 64, 13-21. | 1.8 | 115 |
| 63 | The role of preoperative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary?. <i>Journal of Surgical Oncology</i> , 2018, 117, 207-212. | 1.7 | 22 |
| 64 | Multifocality in Small Bowel Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 303-309. | 1.7 | 59 |
| 65 | Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15. | 3.0 | 129 |
| 66 | Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 17-23. | 1.4 | 58 |
| 67 | Long-Term Outcomes after Elective versus Emergency Surgery for Small Bowel Neuroendocrine Tumors. <i>American Surgeon</i> , 2018, 84, 1570-1574. | 0.8 | 15 |
| 68 | Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32. | 4.0 | 29 |
| 69 | The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. <i>Modern Pathology</i> , 2018, 31, 1523-1531. | 5.5 | 41 |
| 70 | Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. <i>Npj Digital Medicine</i> , 2018, 1, 27. | 10.9 | 111 |
| 71 | Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. <i>Clinical Cancer Research</i> , 2018, 24, 5018-5027. | 7.0 | 158 |
| 72 | Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 777-786. | 4.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46. | | 135 |
| 74 | Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature. American Journal of Dermatopathology, 2018, 40, 927-929. | 0.6 | 3 |
| 75 | Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 125-135. | 27.0 | 2,206 |
| 76 | Statins and pancreatic cancer. Oncology Letters, 2017, 13, 1035-1040. | 1.8 | 40 |
| 77 | Private Funding for Pancreatic Cancer Research: More Than a Chip Shot. Gastroenterology, 2017, 152, 918-921.e2. | 1.3 | 3 |
| 78 | Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. Journal of Nuclear Medicine, 2017, 58, 1793-1796. | 5.0 | 24 |
| 79 | Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy. JAMA Oncology, 2017, 3, 516. | 7.1 | 142 |
| 80 | Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. Clinical Therapeutics, 2017, 39, 2135-2145. | 2.5 | 12 |
| 81 | Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. Journal of Thoracic Oncology, 2017, 12, 425-436. | 1.1 | 161 |
| 82 | Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors. American Surgeon, 2017, 83, 1174-1178. | 0.8 | 10 |
| 83 | A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget, 2017, 8, 83446-83456. | 1.8 | 54 |
| 84 | Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. Journal of Gastrointestinal Oncology, 2017, 8, 127-138. | 1.4 | 62 |
| 85 | Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 555-562. | 4.9 | 79 |
| 86 | Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian Journal of Urology, 2016, 3, 240-253. | 1.2 | 33 |
| 87 | Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology, 2016, 4, 315-325. | 1.0 | 31 |
| 88 | Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS ONE, 2016, 11, e0152172. | 2.5 | 43 |
| 89 | Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. Journal of Gastrointestinal Oncology, 2016, 7, 239-47. | 1.4 | 8 |
| 90 | Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Medical Dosimetry, 2015, 40, 47-52. | 0.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 1040-1048. | 9.4 | 226 |
| 92 | Review of systemic therapies for locally advanced and metastatic rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 185-200. | 1.4 | 45 |
| 93 | Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3299-3306. | 1.6 | 132 |
| 94 | Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1051-1061. | 2.4 | 3 |
| 95 | Pretreatment [18F] FDG-PET texture analysis to predict local response of pancreatic cancer to radiotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 375-375. | 1.6 | 2 |
| 96 | A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed. <i>World Journal of Oncology</i> , 2013, 4, 217-220. | 1.5 | 1 |
| 97 | A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era. <i>Sarcoma</i> , 2012, 2012, 1-10. | 1.3 | 323 |
| 98 | Gender Disparities in Metastatic Colorectal Cancer Survival. <i>Clinical Cancer Research</i> , 2009, 15, 6391-6397. | 7.0 | 168 |
| 99 | Myositis ossificans: A case report. <i>Arthritis and Rheumatism</i> , 2005, 53, 793-795. | 6.7 | 20 |